Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.

ABSTRACT:

Background

The use of 5-hydroxytryptamine-3 receptor antagonists (5HT₃RA) has long been considered the standard regimen for preventing chemotherapy-induced nausea and vomiting (CINV) prior to hematopoietic stem cell transplantation (HSCT). However, their therapeutic outcomes have been unsatisfactory. NEPA, an oral formulation combining the neurokinin-1 receptor antagonist netupitant and the 5HT₃RA palonosetron, has received regulatory approval for the management of highly and moderately emetogenic chemotherapy. This study aims to compare the efficacy of NEPA with that of 5HT₃RA alone in preventing CINV among patients undergoing multiday conditioning chemotherapy prior to HSCT.

Patients and methods

We conducted a retrospective analysis of pati

SUBMITTER: Zhang H 

PROVIDER: S-EPMC10703172 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature